Search bioRxivSearch

bioRxiv · 10.1101/290684

How to control for confounds in decoding analyses of neuroimaging data

Abstract

Over the past decade, multivariate pattern analyses and especially decoding analyses have become a popular alternative to traditional mass-univariate analyses in neuroimaging research. However, a fundamental limitation of decoding analyses is that the source of information driving the decoder is ambiguous, which becomes problematic when the to-be-decoded variable is confounded by variables that are not of primary interest. In this study, we use a comprehensive set of simulations and analyses of empirical data to evaluate two techniques that were previously proposed and used to control for confounding variables in decoding analyses: counterbalancing and confound regression. For our empirical analyses, we attempt to decode gender from structural MRI data when controlling for the confound brain size. We show that both methods introduce strong biases in decoding performance: counterbalancing leads to better performance than expected (i.e., positive bias), which we show in our simulations is due to the subsampling process that tends to remove samples that are hard to classify; confound regression, on the other hand, leads to worse performance than expected (i.e., negative bias), even resulting in significant below-chance performance in some scenarios. In our simulations, we show that below-chance accuracy can be predicted by the variance of the distribution of correlations between the features and the target. Importantly, we show that this negative bias disappears in both the empirical analyses and simulations when the confound regression procedure performed in every fold of the cross-validation routine, yielding plausible model performance. From these results, we conclude that foldwise confound regression is the only method that appropriately controls for confounds, which thus can be used to gain more insight into the exact source(s) of information driving ones decoding analysis.\n\nHIGHLIGHTSO_LIThe interpretation of decoding models is ambiguous when dealing with confounds;\nC_LIO_LIWe evaluate two methods, counterbalancing and confound regression, in their ability to control for confounds;\nC_LIO_LIWe find that counterbalancing leads to positive bias because it removes hard-to-classify samples;\nC_LIO_LIWe find that confound regression leads to negative bias, because it yields data with less signal than expected by chance;\nC_LIO_LIOur simulations demonstrate a tight relationship between model performance in decoding analyses and the sample distribution of the correlation coefficient;\nC_LIO_LIWe show that the negative bias observed in confound regression can be remedied by cross-validating the confound regression procedure;\nC_LI

Source connections

Explore related subjects

Keep this discovery

BibTeXRIS

Snoek, L., Miletic, S., Scholte, H. S.. 2018-03-28. How to control for confounds in decoding analyses of neuroimaging data. https://doi.org/10.1101/290684

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience